Results of pre-clinical and early clinical trials conducted by investigators at the National Institutes of Health showing the effectiveness of using bacteria to treat eczema are paving the way for further study into the potential for microbiome-based therapy to treat this common skin disease.
SkinBioTherapeutics (LON:SBTX) is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O’Neill and Professor Andrew McBain at The University of Manchester.
The SkinBioTherapeutics’ platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, improve repair and reduce bacterial load.